Introduction
============

Metabolic syndrome is a conglomeration of interrelated risk factors that are associated with obesity and the development of atherosclerotic cardiovascular disease.[@b1-dmso-10-393] International consortiums dedicated to cardiovascular and metabolic health recognize metabolic syndrome as a chronic disease that causes significant loss of productivity, excess mortality, and a significant expenditure of healthcare dollars.[@b2-dmso-10-393]

Bariatric surgery, an effective treatment for obesity[@b3-dmso-10-393],[@b4-dmso-10-393] and type 2 diabetes mellitus (T2DM),[@b5-dmso-10-393],[@b6-dmso-10-393] also improves metabolic syndrome and reduces cardiovascular mortality in cohorts followed up for 5--18 years after surgery.[@b7-dmso-10-393]--[@b10-dmso-10-393] We assume, but do not have supporting evidence for, similar improvements in metabolic syndrome after sleeve gastrectomy (SG), which has surpassed Roux-en-Y gastric bypass (RYGB) as the most commonly performed bariatric operation in the USA (52% vs 27% in 2014).[@b11-dmso-10-393]

RYGB may yield greater weight loss than SG, but differences in the remission of comorbidities and complication rates are less well-studied. Most SG studies have limited follow-up and are unable to report on the durability of weight loss or improvements in metabolic syndrome.[@b12-dmso-10-393]--[@b15-dmso-10-393] Moreover, most bariatric studies predominantly enroll female subjects, and although weight loss results may be similar between sexes, metabolic improvements or complication rates may not be generalizable to men.[@b16-dmso-10-393],[@b17-dmso-10-393]

In this study, we retrospectively evaluated the remission of metabolic syndrome and its individual components 4 years after RYGB or SG in a US veteran population. In addition, we examined the complication rates of both the operations.

Methods
=======

Study design and patients
-------------------------

This was a retrospective review of the electronic medical records of all consecutive patients who underwent either RYGB or SG at the Dallas Veterans Affairs Medical Center in Dallas, TX, USA from 2003 to 2012. The center's institutional review board approved the study. Obtaining patient consents was waived as this was a retrospective study with minimal risks. All patients met the criteria for bariatric surgery set by the National Institutes of Health consensus conference.[@b3-dmso-10-393] Patients with a body mass index (BMI) of \>40 kg/m^2^ or with a BMI of \>35 kg/m^2^ and one or more significant comorbid conditions, including T2DM, hyperlipidemia, and hypertension, were offered bariatric surgery. The choice of bariatric procedure was based on patient preference, perioperative risk assessment by the bariatric team, instrument availability, and the adoption of new operations (no SGs were performed prior to 2007). Patients were allowed to choose either operation if they did not have cirrhosis, end-stage renal disease, or cardiac dysfunction that limited activities of daily living. Otherwise SG was offered. The preoperative risk assessment was conducted by the bariatric team, which included surgeons, hepatologists, nephrologists, and cardiologists. Instrument availability refers to a 6-month period when RYGB instruments were not available and the patients could either undergo an SG or postpone their operation until all instruments were again available.

Operative procedures
--------------------

### RYGB

Roux limbs of \~110 cm, gastric pouches of 20--30 mL, and jejunojejunostomies 40--45 cm distal to the ligament of Treitz were created. The open RYGBs (88%) had hand-sewn gastrojejunostomies and jejunojejunostomies; the gastric pouches were created with a TA 60 stapler (Medtronic, Minneapolis, MN, USA). Open gastrojejunostomies were anti-gastric with retrocolic Roux limbs. Leak tests were not performed. The laparoscopic RYGBs (12%) had 25 mm circular endostapled gastrojejunostomies and 60 mm endostapled jejunojejunostomies. Leak tests were performed with an esophagoduodenoscopy insufflation, distal occlusion, and submersion in sterile saline.

### SG

The gastrosplenic omentum was dissected from 8 cm proximal to the pylorus to the level of the left crus of the diaphragm. The angle of His was completely mobilized. A 32-French calibration bougie was advanced into the stomach and a longitudinal restrictive gastrectomy was performed using buttressed endostaplers. Care was taken to reduce the posterior fundus throughout the dissection. A leak test was performed with an esophagoduodenoscopy insufflation, distal occlusion, and submersion in sterile saline. All sleeve gastrectomies were performed laparoscopically.

Data collection
---------------

Study coordinators and surgical residents were trained to collect the following patient information from the electronic medical record: demographics, weight, height, hemoglobin A1c (HbA1c), fasting blood glucose levels, blood pressures, lipid panels, medication usage for T2DM, hypertension and hyperlipidemia, and late surgical complications (\>30 days postsurgery). Measurement time points were at baseline (preoperation) and a minimum of 4 years postoperation. Weight was extracted annually for up to 4 years.

Outcome variables
-----------------

Weight loss outcomes were reported as the change in weight, BMI, percent of total weight loss, and excess weight loss (EWL). T2DM was defined as HbA1c of ≥6.5% or the use of diabetes medications. Metabolic syndrome was defined as having three or more of the following criteria:[@b18-dmso-10-393] Fasting blood glucose of ≥100 mg/dL (≥5.6 mmol/L), HbA1c of ≥5.7%, a diagnosis of T2DM, or a prescription for diabetes medication.[@b19-dmso-10-393]BMI of ≥30 kg/m^2^ as a surrogate for waist circumference of ≥102 cm (male) and ≥89 cm (female).Triglycerides (TGs) of ≥150 mg/dl, or a prescription for hypertriglyceridemia medication.High-density lipoprotein cholesterol (HDL-C) of \<40 mg/dL for males (\<2.2 mmol/L) or \<50 mg/dL for females (\<2.8 mmol/L).Hypertension defined as blood pressure of ≥130/85 mm Hg or a prescription for antihypertensive medication.

Statistical analyses
--------------------

Results are expressed as means with standard deviations and count frequencies with percentages unless otherwise specified. Categorical outcomes were compared between the two groups with Fisher's exact test, and continuous variables were compared with a two-sample *t* test or Wilcoxon rank sum test. Changes in weight through 4 years of follow-up were compared between the SG and RYGB groups with mixed effects repeated measures linear models. In patients with established metabolic syndrome prior to surgery, logistic regression was used to assess presurgery predictors of metabolic syndrome persistence. Independent variables included in the logistic models were gender, age, and BMI; metabolic variables were included where *P*\<0.20.

Due to baseline imbalances of weight and metabolic characteristics between the SG and RYGB groups, a sensitivity analysis was performed using propensity score matching. Multiple logistic regression was implemented to generate a propensity score for all patients according to the type of operation (RYGB vs SG), with the following covariates: age, gender, race/ethnicity (African American, non-Hispanic white, others), presurgery weight, BMI, the presence of diabetes and dyslipidemia, and metabolic syndrome features of elevated glucose, blood pressure, TGs, and low HDL cholesterol. Patients in the two groups were then matched through a greedy 8-1 digit-matching algorithm resulting in 65 RYGB and 65 SG patients. Standardized differences between groups were assessed to establish whether adequate balance was achieved. Analyses were then performed on the two matched groups.

Unless otherwise noted, two-sided *P* values of ≤0.05 were considered statistically significant. Analyses were conducted using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).

Results
=======

Baseline characteristics
------------------------

The cohort consisted of all 266 consecutive patients who underwent bariatric surgery during the study period. Data were available for 254 patients (96% of the total cohort; 10 deceased, 244 alive, 12 lost to follow-up) at 4 years ([Figure S1](#SD1-dmso-10-393){ref-type="supplementary-material"}). While all patients had annual weight and complications data, 6 patients were missing complete data on metabolic syndrome criteria, yielding 238 patients available for the assessment of metabolic syndrome. Patients underwent RYGB (n = 141; 59%) or SG (n = 97; 41%). The mean age of the cohort was 51.4 years with a male (59%) and Caucasian (69%) predominance. The baseline characteristics by group according to operation are summarized in [Table 1](#t1-dmso-10-393){ref-type="table"}. The groups had similar mean ages and gender/race frequencies. The RYGB group weighed significantly more than the SG group, with a mean preoperative weight of 137 kg compared to 124 kg (*P*\<0.01), and a mean preoperative BMI of 45.5 kg/m^2^ compared to 40.7 kg/m^2^ (*P*\<0.01), respectively.

RYGB patients were more likely to have hypertension (RYGB 96.5% vs SG 87.6%; *P*=0.02) and hypertriglyceridemia (RYGB 59.7% vs SG 37.9%; *P*\<0.01). The prevalence of hyperglycemia and low HDL was similar between groups.

Metabolic syndrome remission
----------------------------

RYGB significantly reduced all metabolic syndrome components, while SG significantly reduced all metabolic syndrome components except hypertriglyceridemia and hyperglycemia ([Table 2](#t2-dmso-10-393){ref-type="table"}). More patients who underwent RYGB achieved a BMI of \<30 kg/m^2^ compared to SG (31.9% vs 17.5%; *P*=0.02). In addition, RYGB was associated with a greater decrease in the prevalence of hypertriglyceridemia (from 60.1% to 21.7%) compared to SG (from 37.2% to 29.8%; *P*\<0.01). There was no significant difference between operations in improving hyperglycemia, low HDL, or hypertension.

Metabolic syndrome remission occurred in both the surgical groups, but there was no significant difference of remission rates between the RYGB (37.6%) and the SG group (26.8%; *P*=0.09). With propensity matching, similar metabolic syndrome remission was again found after both operations (RYGB 40.0%, SG 27.7%; *P*=0.34; [Table S1](#SD2-dmso-10-393){ref-type="supplementary-material"}).

The effect of surgery on metabolic syndrome was determined for the whole cohort after adjusting for clinically and statistically significant factors affecting the outcomes ([Table 3](#t3-dmso-10-393){ref-type="table"}). We found that SG patients had a 1.89 odds ratio (OR) (95% CI, 0.91--3.91) of having persistent metabolic syndrome at 4 years compared to RYGB patients, which supports our analysis in the matched and unmatched cohort that there may be no significant difference between both operations on metabolic syndrome remission at 4 years.

Predictors of metabolic syndrome persistence 4 years post operation were male gender (OR, 2.28; 95% CI, 1.14--4.56), a preoperative diagnosis of T2DM (OR, 3.33; 95% CI, 1.71--6.50), and preoperative low HDL (OR, 2.28; 95% CI, 1.17--4.48).

Weight change
-------------

RYGB patients lost more weight than SG patients at 4 years post operation ([Figure 1](#f1-dmso-10-393){ref-type="fig"}). The mean weight loss after RYGB was 36.3 kg (*P*\<0.01) and 13.4 kg after SG (*P*\<0.01). The percentage weight loss was 26.5% at 4 years after RYGB and 10.8% after SG (*P*\<0.01, each pre- vs postoperation). The greatest percent weight change for both the operations occurred at 1 year (RYGB 28.7%, SG 16.8%). The decrease in BMI and weight were more pronounced in RYGB. After propensity matching, a similar weight loss trend and magnitude were found ([Figure 2](#f2-dmso-10-393){ref-type="fig"}).

Complications
-------------

From 1 to 4 years after surgery, 7 patients (4.4%) died after RYGB, and 3 (2.8%) died after SG. RYGB was associated with a greater rate of morbidity compared to SG ([Table 4](#t4-dmso-10-393){ref-type="table"}). RYGB had significantly greater rates of reoperation, cholecystectomy, ulcer, and vitamin B~12~ deficiency. These significant differences persisted after propensity matching. No significant differences occurred in rates of vitamin D or iron deficiency, chronic nausea, vomiting, or abdominal pain in the matched cohort.

Discussion
==========

This study presents 4-year outcome data on metabolic syndrome, weight loss, and complications after SG and RYGB in a near-complete cohort of US veterans. In spite of significantly more weight loss in the RYGB cohort, the difference in metabolic syndrome remission was not significantly greater than for SG, but the rate of postoperative complications was higher in the RYGB group.

At 4 years of follow-up, both RYGB and SG reduced the prevalence of metabolic syndrome by 37.6% and 26.8%, respectively. Weight loss was greatest in both the groups after the first year (RYGB 28.7% vs SG 16.8%; *P*\<0.01), with weight regain occurring after the first year in the SG group and after the second year in the RYGB group.

Few studies report the effect of bariatric surgery on metabolic syndrome but instead focus on individual components such as hypertension, hypertriglyceridemia, hyperglycemia, or T2DM.[@b20-dmso-10-393] Reporting the effect of bariatric surgery on metabolic syndrome as an aggregate of cardiovascular risk factors, instead of its individual components, is helpful in quantifying the magnitude of metabolic improvement and projected decrease in cardiovascular morbidity and mortality between these two procedures.[@b21-dmso-10-393]--[@b23-dmso-10-393] The majority of bariatric studies reporting the effect of surgery on metabolic syndrome involve subjects who have undergone RYGB and not SG. To our knowledge, this is the first 4-year study reporting the effect of both RYGB and SG on metabolic syndrome.

The remission rates of metabolic syndrome in our cohort at 4-year follow-up were lower than those reported from other groups. Studies following patients from 6 to 36 months after surgery yielded remission rates of 58%--96%.[@b24-dmso-10-393]--[@b27-dmso-10-393] Shah et al, at a minimum of 5 years after RYGB, reported a metabolic syndrome remission rate of 86%.[@b28-dmso-10-393] In general, these studies followed younger and predominantly female cohorts with a lower baseline prevalence of metabolic syndrome, assessed outcomes after RYGB, used different definitions of metabolic syndrome,[@b29-dmso-10-393],[@b30-dmso-10-393] and had greater cohort attrition. Batsis et al reporting on metabolic syndrome for both RYGB and SG at \~3 years after surgery, with similar baseline prevalence to our study, also reported higher metabolic syndrome remission rates of 58% and 59% (RYGB and SG, respectively).[@b31-dmso-10-393] Similar to our findings, Batsis et al found no significant difference in metabolic syndrome remission between operations. It is challenging to compare the results across studies because of differences in the study populations, baseline prevalence of metabolic syndrome, definition criteria for metabolic syndrome, and follow-up intervals. Overall, bariatric surgery is effective at reducing the prevalence of metabolic syndrome and the risk of cardiovascular events.

In this study, RYGB was similar to SG with respect to the remission of hyperglycemia and hypertension. However, the decrease in the prevalence of hyperglycemia in the SG group did not reach statistical significance in spite of similarities in baseline fasting glucose, HbA1c, the prevalence of diabetes, and insulin use between the surgical groups. This difference may be explained by the greater magnitude of weight loss in the RYGB group. The RYGB group experienced a greater reduction in the prevalence of hypertriglyceridemia than the SG group. Malabsorption resulting from decreased exposure of digested food to intestinal villi after RYGB may explain the greater improvement in TG level versus SG. Also, the magnitude of the reduction of TGs has been shown to be directly related to the amount of weight lost.[@b32-dmso-10-393],[@b33-dmso-10-393] The greater degree of weight loss alone, in the RYGB group, may explain the greater reducing of hypertriglyceridemia versus SG.

Randomized controlled trials have demonstrated similar efficacy of SG and RYGB for weight loss[@b13-dmso-10-393],[@b34-dmso-10-393],[@b35-dmso-10-393] or diabetes.[@b5-dmso-10-393] These studies had relatively small sample sizes and varying follow-up times and are not always powered to detect the differences between the operations. Large retrospective studies have shown, similar to our results, that RYGB seems to be more effective than SG for weight reduction.[@b36-dmso-10-393],[@b37-dmso-10-393] The Michigan Bariatric Surgery Collaborative found that RYGB patients had more weight loss than SG (67% vs 56%, respectively; *P*=0.0004) at a 3-year follow-up. However, weight loss data were available for \<4% of subjects at the 3-year time point.[@b36-dmso-10-393] RYGB may lead to greater weight loss in men than in women when compared with SG. It is proposed that the combination of gastric restriction and malabsorption from the intestinal bypass in RYGB makes it a more effective weight loss operation than SG's gastric restriction alone. There is also evidence for significantly greater levels of glucagon-like peptide-1, a hormone conferring satiety,[@b34-dmso-10-393] postoperatively and up to 1 year after RYGB versus SG, perhaps contributing to greater weight loss within the first year of surgery or beyond.

A recent study in veterans compared 1785 patients who underwent RYGB with 379 who underwent SG.[@b37-dmso-10-393] Those in the RYGB group lost significantly more total weight than those in the SG group (27.5%, 95% CI, 23.8%--31.2% vs 17.8%, 95% CI, 9.7%--25.9%, respectively). This study had a follow-up rate of 47.7% for the SG group, which may have led to an overestimation of treatment results. Despite the potential overestimation of weight loss, our study, with a follow-up rate of 96%, supports weight loss consistent with the confidence limits reported by Maciejewski et al[@b37-dmso-10-393] and the finding of greater weight loss after RYGB than SG at 4 years.

The favorable complication rate of SG relative to RYGB is consistent with the short-term postoperation literature.[@b35-dmso-10-393],[@b38-dmso-10-393] Limited data is available on the long-term complications, particularly after SG.[@b14-dmso-10-393] The greater reoperation rate over 4 years after RYGB was attributable to incisional hernia repairs, perforated gastric ulcers, bowel obstructions from adhesions, and gastrojejunal strictures after failed endoscopic dilation. The majority of RYGB were performed using an open approach; fewer reoperations for incisional hernia would be expected had the approach been laparoscopic.[@b39-dmso-10-393] The higher rate of ulcers after RYGB is due to the presence of a gastrojejunal anastomosis leading to marginal ulceration from acid-mediated erosions of the jejunal mucosa and/or from ischemia.[@b40-dmso-10-393] This does not occur with SG as normal continuity of the upper gastrointestinal system is not interrupted, nor is there an anastomosis. Vitamin B~12~ deficiency is more common following RYGB because the gastric pouch of the RYGB is composed mostly of gastric cardia and is smaller than the residual stomach in SG, leading to a near-exclusion of intrinsic factor-producing parietal cells. Intrinsic factor, required for vitamin B~12~ absorption, is either absent or produced at very low levels, resulting in B~12~ deficiency if not supplemented. Also, intestinal bypass malabsorption and/or dumping syndrome after RYGB may contribute to the deficiency in vitamin B~12~ and other nutrients.

Limitations of this study include its retrospective design, which can introduce selection bias and incomplete data collection. While we attempted to reduce bias with a secondary propensity-matched analysis, factors not captured or unknown may affect the outcomes. BMI was used as a surrogate for waist circumference in keeping with the International Diabetes Federation definition of metabolic syndrome, as waist circumferences were not routinely collected. This substitution could affect the baseline prevalence of metabolic syndrome but should not affect the pre- and postoperative comparisons. In addition, this study evaluated a predominantly male and lower socioeconomic level population, which may limit its generalizability. Most bariatric populations are predominantly female and, aside from Medicare patients, represent a higher socioeconomic class of privately insured or self-pay patients. Finally, we did not have information on changes in other weight-dependent comorbidities such as obstructive sleep apnea, mechanical joint disease, and urinary incontinence. Despite these limitations, the duration of follow-up, the high degree of cohort retention, and the reporting of complications provided a unique opportunity for evaluating the relative treatment benefits in this population.

Conclusion
==========

This study shows that in a US veteran population, RYGB and SG procedures were associated with similar rates of remission of metabolic syndrome at 4 years in spite of greater weight loss and complications in the RYGB group. Though a long-term randomized trial comparing the effects of both the operations on metabolic syndrome remission as well as the associated risks of surgery may clarify/validate our findings, the feasibility and cost of such a trial preclude the likelihood of it occurring.

Supplementary materials
=======================

###### 

Flowchart of cohort sample size for analyses.

**Abbreviations:** MetS, metabolic syndrome; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy; VA, Veterans Affairs.

###### 

Prevalence of metabolic syndrome and its components before ("Pre") and 4 years following ("Post") RYGB and SG for the matched cohort

                         RYGB (n = 65)   Paired test *P*-value (McNemar)   SG (n = 65)   Paired test *P*-value (McNemar)   Interaction *P*-value            
  ---------------------- --------------- --------------------------------- ------------- --------------------------------- ----------------------- -------- --------
  Obesity                65 (100)        39 (60.0)                         \<0.01        65 (100)                          57 (87.7)               \<0.01   \<0.01
  Hyperglycemia          51 (78.5)       40 (61.5)                         0.01          49 (75.4)                         45 (75.0)               0.74     0.06
  Hypertriglyceridemia   32 (50)         8 (12.5)                          \<0.01        31 (49.2)                         22 (34.4)               0.039    \<0.01
  Low HDL-C              33 (51.6)       10 (15.6)                         \<0.01        31 (49.2)                         11 (17.5)               \<0.01   0.68
  Hypertension           61 (93.9)       55 (84.6)                         0.03          62 (95.4)                         43 (66.2)               \<0.01   0.09
  Metabolic syndrome     57 (87.7)       31 (47.7)                         \<0.01        57 (87.7)                         39 (60.0)               \<0.01   0.34

**Abbreviations:** HDL-C, high-density lipoprotein cholesterol; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy
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![Weight (kg), body mass index (kg/m^2^), percent weight change (%), and excess weight loss (%) per procedure type for the matched cohort.\
**Abbreviations:** BMI, body mass index; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.](dmso-10-393Fig2){#f2-dmso-10-393}

###### 

Patients' demographics and baseline comorbidities

  -----------------------------------------------------------------------------------------------------------------------------------------
  Characteristics                       Overall cohort      Matched cohort                                                           
  ------------------------------------- ------------------- ----------------- -------- ------------------ ------------------ ------- ------
  Age, years                            51.1 (8.1)          51.9 (10.4)       0.53     50.9 (9.1)         51.5 (10.1)        0.06    0.72

  Males, n (%)                          80 (56.7)           61 (62.9)         0.35     37 (56.9)          29 (60.0)          0.06    0.86

  Race, n (%)                                                                 0.11                                                   0.78

   Caucasian                            104 (73.8)          60 (61.9)                  40 (61.5)          44 (67.7)          0.13    

   African American                     24 (17.0)           21 (21.7)                  16 (24.6)          14 (21.5)          0.07    

   Other                                13 (9.2)            16 (16.5)                  9 (13.9)           7 (10.8)           0.09    

  Weight, kg                            137 (26)            124 (23)          \<0.01   126 (20)           126 (22)           0.01    0.95

  BMI, kg/m^2^                          45.5 (6.4)          40.7 (4.8)        \<0.01   42.0 (4.8)         42.1 (4.6)         0.01    0.95

  Hyperglycemia, n (%)                  103 (73.1)          77 (79.4)         0.29     50 (76.9)          49 (75.4)          0.04    1.0

  Type 2 diabetes, n (%)                78 (55.3)           47 (48.5)         0.36     33 (50.8)          30 (46.2)          0.09    0.73

  HbA1c, %                              6.6 (1.2)           6.7 (1.2)         0.73     6.7 (1.3)          6.6 (1.2)          0.15    0.50

  Fasting plasma glucose, mg/dL         125 (48)            121 (43)          0.57     120 (38)           120 (37)           0.004   0.98

  Oral diabetes medication, n (%)       63 (44.7)           37 (38.1)         0.35     26 (40.0)          24 (36.9)          0.06    0.86

  Insulin treatment, n (%)              26 (18.4)           22 (22.7)         0.51     12 (18.5)          14 (21.5)          0.08    0.83

  Insulin total daily dose, U           139 \[80---169\]\   90 \[60--155\]\   0.54     140 \[80--190\]\   110 \[65--190\]\   0.16    0.74
                                        n = 24              n = 18                     n = 11             n = 12                     

  Hypertension, n (%)                   136 (96.5)          85 (87.6)         0.02     61 (93.9)          62 (95.4)          0.07    1.0

  Systolic blood pressure, mm Hg        132 (16)            131 (14)          0.52     133 (18)           130 (13)           0.19    0.30

  Diastolic blood pressure, mm Hg       73 (11)             75 (10)           0.15     75 (11)            75 (11)            0.05    0.76

  Hypertension medication, n (%)        116 (82.3)          70 (72.2)         0.08     50 (76.9)          51 (78.5)          0.04    1.0

  Hypertriglyceridemia, n (%)           83 (59.7)           36 (37.9)         \<0.01   32 (50.0)          31 (49.2)          0.02    1.0

  Triglycerides, mg/dL                  174 \[108--229\]    122 \[89--200\]   0.01     162 \[92--239\]    153 \[102--216\]   0.04    0.82

  Low high-density lipoprotein, n (%)   70 (50.4)           46 (48.4)         0.79     33 (51.6)          31 (49.2)          0.05    0.86

  HDL, mg/dL                            44 (12)             43 (13)           0.6      42 (11)            44 (12)            0.10    0.58

  Lipid-lowering medication, n%         82 (58.2)           59 (60.8)         0.69     38 (58.5)          40 (61.5)          0.06    0.86
  -----------------------------------------------------------------------------------------------------------------------------------------

**Notes:** Continuous variables are summarized as mean (standard deviation) or median \[25th--75th percentile\]. For skewed variables, the parametric and nonparametric comparisons are very similar (nonparametric reported for insulin dose and triglycerides).

**Abbreviations:** BMI, body mass index; HDL, high-density lipoprotein; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.

###### 

Prevalence of metabolic syndrome and its components before ("pre") and 4 years following ("post") RYGB and SG for the entire cohort

                         RYGB (n = 141)   Paired test *P*-value (McNemar)   SG (n = 92)   Paired test *P* (McNemar)   Interaction *P*-value            
  ---------------------- ---------------- --------------------------------- ------------- --------------------------- ----------------------- -------- --------
  Obesity                141 (100)        96 (68.1)                         \<0.01        97 (100)                    80 (82.5)               \<0.01   0.02
  Hyperglycemia          106 (75.2)       89 (63.1)                         \<0.01        74 (81.3)                   67 (73.6)               0.09     0.53
  Hypertriglyceridemia   83 (60.1)        30 (21.7)                         \<0.01        35 (37.2)                   28 (29.8)               0.18     \<0.01
  Low HDL-C              69 (50)          31 (22.5)                         \<0.01        45 (48.4)                   15 (16.1)               \<0.01   0.38
  Hypertension           136 (96.5)       118 (83.7)                        \<0.01        85 (87.6)                   65 (67.0)               \<0.01   0.45
  Metabolic syndrome     125 (88.7)       72 (51.1)                         \<0.01        82 (84.5)                   56 (57.7)               \<0.01   0.09

**Abbreviations:** HDL-C, high-density lipoprotein cholesterol; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.

###### 

Predictors of metabolic syndrome presence at 4-year follow-up using the entire cohort

  MetS at 4-year follow-up   Odds ratio   95% CI
  -------------------------- ------------ ------------
  Surgery type                            
   RYGB                      Ref          
   SG                        1.89         0.91--3.91
  Gender                                  
   Female                    Ref          
   Male                      2.28         1.14--4.56
  Age                        1.05         1.01--1.09
  Preoperative BMI           1.03         0.97--1.09
  Preoperative DM            3.33         1.71--6.50
  Preoperative low HDL       2.28         1.17--4.48

**Abbreviations:** BMI, body mass index; DM, diabetes mellitus; HDL, high-density lipoprotein; MetS, metabolic syndrome; RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.

###### 

\>30 day-morbidity and mortality following RYGB and SG

                                   Entire cohort   Matched cohort                                   
  -------------------------------- --------------- ---------------- -------- ----------- ---------- --------
  Mortality \>30 days              7 (4.4)         3 (2.8)          0.74                            
  Reoperations                     31 (19.5)       3 (2.8)          \<0.01   14 (21.9)   3 (4.8)    \<0.01
  Cholecystectomy                  11 (6.9)        0 (0)            \<0.01   7 (10.9)    0 (0)      0.01
  GI bleed                         2 (1.3)         0 (0)            0.52     2 (3.1)     0 (0)      0.50
  Ulcer                            15 (9.4)        1 (0.9)          \<0.01   7 (10.9)    0 (0)      0.01
  Vitamin B~12~ deficiency         47 (29.6)       8 (7.5)          \<0.01   24 (37.5)   8 (12.9)   \<0.01
  Vitamin D deficiency             6 (3.8)         11 (10.3)        0.04     2 (3.1)     7 (11.3)   0.09
  Iron deficiency                  30 (18.9)       10 (9.4)         0.04     16 (25.0)   8 (12.9)   0.11
  Other nutritional deficiencies   7 (4.4)         1 (0.9)          0.15     3 (4.7)     1 (1.6)    0.62
  Chronic nausea/vomiting          11 (6.9)        3 (2.8)          0.17     7 (10.9)    3 (4.8)    0.32
  Chronic pain                     6 (3.8)         1 (0.9)          0.25     4 (6.3)     1 (1.6)    0.37

**Abbreviations:** RYGB, Roux-en-Y gastric bypass; SG, sleeve gastrectomy.
